Vanda Pharmaceuticals Inc. is challenging the FDA's imposition of a partial clinical hold on its study of the NK1 antagonist tradipitant, saying that the agency has illegally prohibited it from studying the gastroparesis drug in humans for more than 12 weeks "without conducting unnecessary and unethical animal studies," work it said would result in the death of dozens of dogs without producing additional scientific insight.